GREENWICH LIFESCIENCES, INC. Investment Income, Interest
GREENWICH LIFESCIENCES, INC. (GLSI) reported Investment Income, Interest of $72.97 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Income Statement
us-gaap:InvestmentIncomeInterest · last filed 2026-08-11
- GREENWICH LIFESCIENCES, INC. investment income, interest for the quarter ending 2026-06-30 was $72.97K, a 252.94% increase year-over-year.
- GREENWICH LIFESCIENCES, INC. investment income, interest for the quarter ending 2026-03-31 was $68.62K, a 186.26% increase year-over-year.
- GREENWICH LIFESCIENCES, INC. investment income, interest for the quarter ending 2025-12-31 was $22.26K, a 49.35% decline year-over-year.
- GREENWICH LIFESCIENCES, INC. investment income, interest for the quarter ending 2025-09-30 was $22.80K, a 62.22% decline year-over-year.
- GREENWICH LIFESCIENCES, INC. investment income, interest for fiscal 2025 was $89.70K, a 59.78% decline from fiscal 2024.
- GREENWICH LIFESCIENCES, INC. investment income, interest for fiscal 2024 was $223.01K, a 48.86% decline from fiscal 2023.
- GREENWICH LIFESCIENCES, INC. investment income, interest for fiscal 2023 was $436.06K, a 102.80% increase from fiscal 2022.
- GREENWICH LIFESCIENCES, INC. investment income, interest for fiscal 2022 was $215.02K, a 685.68% increase from fiscal 2021.
| Period end | Investment Income, Interest 3 month | Investment Income, Interest 6 month | Investment Income, Interest 9 month | Investment Income, Interest 12 month |
|---|---|---|---|---|
| 2026-06-30 | $72.97K 10-Q · filed 2026-08-11 | $141.59K 10-Q · filed 2026-08-11 | $163.84K derived: sum of 3 quarters · filed 2026-08-11 | $186.64K derived: sum of 4 quarters · filed 2026-08-11 |
| 2026-03-31 | $68.62K 10-Q · filed 2026-06-04 | $90.88K derived: sum of 2 quarters · filed 2026-06-04 | $113.67K derived: sum of 3 quarters · filed 2026-06-04 | $134.35K derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-12-31 | $22.26K derived: 10-K 12 month − 10-Q 9 month · filed 2026-06-01 | $45.05K derived: sum of 2 quarters · filed 2026-06-01 | $65.73K derived: sum of 3 quarters · filed 2026-08-11 | $89.70K 10-K · filed 2026-06-01 |
| 2025-09-30 | $22.80K 10-Q · filed 2025-11-14 | $43.47K derived: sum of 2 quarters · filed 2026-08-11 | $67.44K 10-Q · filed 2025-11-14 | $111.38K derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-06-30 | $20.68K 10-Q · filed 2026-08-11 | $44.65K 10-Q · filed 2026-08-11 | $88.59K derived: sum of 3 quarters · filed 2026-08-11 | $148.93K derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-03-31 | $23.97K 10-Q · filed 2026-06-04 | $67.91K derived: sum of 2 quarters · filed 2026-06-04 | $128.25K derived: sum of 3 quarters · filed 2026-06-04 | $182.97K derived: sum of 4 quarters · filed 2026-06-04 |
| 2024-12-31 | $43.94K derived: 10-K 12 month − 10-Q 9 month · filed 2026-06-01 | $104.28K derived: sum of 2 quarters · filed 2026-06-01 | $159.00K derived: sum of 3 quarters · filed 2026-06-01 | $223.01K 10-K · filed 2026-06-01 |
| 2024-09-30 | $60.34K 10-Q · filed 2025-11-14 | $115.06K derived: sum of 2 quarters · filed 2025-11-14 | $179.07K 10-Q · filed 2025-11-14 | $268.36K derived: sum of 4 quarters · filed 2025-11-14 |
| 2024-06-30 | $54.72K 10-Q · filed 2025-08-14 | $118.73K 10-Q · filed 2025-08-14 | $208.02K derived: sum of 3 quarters · filed 2025-08-14 | $319.16K derived: sum of 4 quarters · filed 2025-08-14 |
| 2024-03-31 | $64.01K 10-Q · filed 2025-05-20 | $153.30K derived: sum of 2 quarters · filed 2025-05-20 | $264.44K derived: sum of 3 quarters · filed 2025-05-20 | $383.89K derived: sum of 4 quarters · filed 2025-05-20 |
| 2023-12-31 | $89.29K derived: 10-K 12 month − 10-Q 9 month · filed 2025-04-15 | $200.43K derived: sum of 2 quarters · filed 2025-04-15 | $319.88K derived: sum of 3 quarters · filed 2025-04-15 | $436.06K 10-K · filed 2025-04-15 |
| 2023-09-30 | $111.14K 10-Q · filed 2024-11-14 | $230.59K derived: sum of 2 quarters · filed 2024-11-14 | $346.77K 10-Q · filed 2024-11-14 | $450.94K derived: sum of 4 quarters · filed 2024-11-14 |
| 2023-06-30 | $119.45K 10-Q · filed 2024-08-14 | $235.63K 10-Q · filed 2024-08-14 | $339.80K derived: sum of 3 quarters · filed 2024-08-14 | $403.84K derived: sum of 4 quarters · filed 2024-08-14 |
| 2023-03-31 | $116.18K 10-Q · filed 2024-05-20 | $220.35K derived: sum of 2 quarters · filed 2024-05-20 | $284.39K derived: sum of 3 quarters · filed 2024-05-20 | $311.62K derived: sum of 4 quarters · filed 2024-05-20 |
| 2022-12-31 | $104.17K derived: 10-K 12 month − 10-Q 9 month · filed 2024-04-15 | $168.21K derived: sum of 2 quarters · filed 2024-04-15 | $195.44K derived: sum of 3 quarters · filed 2024-04-15 | $215.02K 10-K · filed 2024-04-15 |
| 2022-09-30 | $64.04K 10-Q · filed 2023-10-19 | $91.27K derived: sum of 2 quarters · filed 2023-10-19 | $110.85K 10-Q · filed 2023-10-19 | $127.35K derived: sum of 4 quarters · filed 2023-10-19 |
| 2022-06-30 | $27.23K 10-Q · filed 2023-08-21 | $46.81K 10-Q · filed 2023-08-21 | $63.31K derived: sum of 3 quarters · filed 2023-08-21 | $66.88K derived: sum of 4 quarters · filed 2023-08-21 |
| 2022-03-31 | $19.57K 10-Q · filed 2023-05-22 | $36.08K derived: sum of 2 quarters · filed 2023-05-22 | $39.64K derived: sum of 3 quarters · filed 2023-05-22 | $43.34K derived: sum of 4 quarters · filed 2023-05-22 |
| 2021-12-31 | $16.50K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-31 | $20.07K derived: sum of 2 quarters · filed 2023-03-31 | $23.77K derived: sum of 3 quarters · filed 2023-03-31 | $27.37K 10-K · filed 2023-03-31 |
| 2021-09-30 | $3.57K 10-Q · filed 2022-11-14 | $7.27K derived: sum of 2 quarters · filed 2022-11-14 | $10.87K 10-Q · filed 2022-11-14 | |
| 2021-06-30 | $3.70K 10-Q · filed 2022-08-15 | $7.30K 10-Q · filed 2022-08-15 | ||
| 2021-03-31 | $3.60K 10-Q · filed 2022-05-20 | |||
| 2020-12-31 | $832.00 10-K · filed 2022-03-21 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Mereo BioPharma Group plc (MREO) | $0.269B | -9.41 | |
| Akebia Therapeutics, Inc. (AKBA) | United States | $0.255B | -10.35 |
| Sagimet Biosciences Inc. (SGMT) | United States | $0.279B | |
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Lyell Immunopharma, Inc. (LYEL) | United States | $0.248B | -1.32 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Pyxis Oncology, Inc. (PYXS) | United States | $0.244B | |
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |